Frost & Sullivan Recognises Industry's Top Achievers at Healthcare Awards Banquet

Exceptional performances in Europe's healthcare industry were recognised at Frost & Sullivan's prestigious Excellence in Healthcare Awards Banquet held in Dublin yesterday evening. Awardees were drawn from diverse fields ranging from homecare, telecardiology, point-of-care testing and image enhancement technologies to minimally invasive devices, bone densitometry systems, vascular devices and computer-aided detection markets.

Seventeen awards were bestowed over the course of the evening's proceedings. Among the awards presented were those for outstanding market penetration and competitive strategies, product and technology innovation as well as for superior entrepreneurship.

Technology-related awards were conferred on Bioident Technologies Inc., Compumedics, ContextVision, Creganna Medical Devices, Demetech AB and Do- Coop Technologies. Blue Medical, Cerrus International Limited, A. Menarini Diagnostics and Contura were acknowledged for their pioneering product-related endeavours.

Aerotel Medical Systems and the Hartmann Group won acclaim for their growth strategy leadership, while Amphora Research Systems and Medison were commended for their leadership in the categories of market penetration and competitive strategy, respectively.

The successes of small, entrepreneurial companies were also recognised at the awards ceremony. HDH Medical Ltd., im3D – Medical Imaging Lab, and DiaGenic ASA were lauded for demonstrating superior entrepreneurial ability in their respective fields.

Delivering the keynote speech on 'The Four Forces of the Future of Healthcare', Mr. Dorman Followill, Healthcare Practice Director at Frost & Sullivan investigated the global mega-trends determining the future dynamics of the healthcare space.

This year's event was attended by fourteen industry leaders with participants, delegates, and guests commending Europe's top performing healthcare companies.

The following is a complete list of the award recipients:

  • 2007 Product Line Strategy Award – A. Menarini Diagnostics
  • 2007 Innovation & Growth Strategy Leadership of the Year Award in the Home Care and Telecardiology Market – Aerotel Medical Systems
  • 2007 Market Penetration Leadership Award – Amphora Research Systems
  • 2007 Enabling Technology of the Year in the European Point-of-Care Testing Market – Bioident Technologies Inc.
  • 2007 Product Innovation Award – Blue Medical
  • 2007 Product Innovation Award – Cerrus International Limited
  • 2006 Technology Leadership Award – Compumedics
  • 2007 Global Enabling Technology of the Year Award in the Image Enhancement Market – ContextVision
  • 2007 Product Differentiation Innovation Award – Contura
  • 2007 Technology Innovation of the Year Award in the Minimally Invasive Devices Market – Creganna Medical Devices
  • 2007 Technology Innovation in the European Bone Densitometry Systems Market – Demetech AB
  • 2007 Entrepreneurial Company Award – DiaGenic ASA
  • 2007 Technology Leadership Award – Do- Coop Technologies
  • 2007 Growth Strategy Leadership Award – Hartmann Group
  • 2007 Entrepreneurial Company of the Year Award in the European Vascular Device Market – HDH Medical Ltd.
  • 2007 Entrepreneurial Company of the Year Award in the European Computer Aided Detection Markets - im3D- Medical Imaging Lab
  • 2007 Competitive Strategy Leadership Award – Medison

About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit www.frost.com.

Most Popular Now

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...